文献速递心力衰竭与心肌病

静脉铁剂治疗心力衰竭:铁缺乏定义与临床反应——IRONMAN 试验

Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
PubMed 文献 · Eur Heart J · 2024-01-01

IRONMAN 试验纳入 1137 例射血分数≤45% 且铁蛋白<100 µg/L 或 TSAT<20% 的心衰患者,随机接受静脉羧基麦芽糖铁(FDI)或常规治疗。假设生成性分析提示,贫血或 TSAT<20% 且铁蛋白>100 µg/L 可能识别更能从静脉铁剂获益的患者,尚需验证。

要点

  • 基线 TSAT 越低、铁蛋白越低、贫血越重,FDI 后血红蛋白升幅越大。
  • 无贫血或 TSAT≥20% 者事件率较低,FDI 获益证据少。
  • 贫血或 TSAT<20%(尤其铁蛋白≥100 µg/L)者事件率更高,FDI 绝对事件下降更大但未达统计学显著。

核心结论

  • 贫血或 TSAT<20% 且铁蛋白>100 µg/L 可能识别更能从静脉铁剂获益的心衰患者,该解释需确认。

研究设计与样本

  • IRONMAN 试验随机对照分析,纳入 1137 例心衰且射血分数≤45%、血清铁蛋白<100 µg/L 或 TSAT<20% 的患者,随机接受静脉 FDI 或常规治疗。

主要发现

  • 校正常规治疗后,FDI 后血红蛋白升幅在基线 TSAT 越低(Pinteraction<.0001)、铁蛋白越低(Pinteraction=.028)、贫血越重(Pinteraction=.014)时越大。
  • 4 个月 MLwHF 评分在贫血更重患者中 FDI 组略低(更好)(总体 Pinteraction=.14;躯体 Pinteraction=.085;情绪 Pinteraction=.043),但与基线 TSAT 或铁蛋白无关。
  • 血液检测未预测 FDI 组与对照组之间 6 分钟步行距离的差异。
  • 无贫血或 TSAT≥20% 与较低事件率相关,且 FDI 获益证据少。
  • 贫血更重或 TSAT<20%(尤其铁蛋白≥100 µg/L)与更高事件率相关,FDI 绝对事件下降更大但未达统计学显著。

关键数值与推荐

  • 铁缺乏定义:血清铁蛋白<100 µg/L 或 TSAT<20%。
  • 贫血更重或 TSAT<20% 尤其铁蛋白≥100 µg/L 者事件率更高。
  • 无贫血或 TSAT≥20% 者事件率较低且 FDI 获益证据少。

临床怎么用

  • 对心衰合并贫血或 TSAT<20% 且铁蛋白>100 µg/L 的患者,可考虑静脉铁剂治疗可能带来更大获益。
  • 无贫血且 TSAT≥20% 的患者,静脉铁剂获益证据有限。

局限性

  • 该分析为假设生成性,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: What is the relationship between blood tests for iron deficiency, including anaemia, and the response to intravenous iron in patients with heart failure? METHODS: In the IRONMAN trial, 1137 patients with heart failure, ejection fraction ≤ 45%, and either serum ferritin < 100 µg/L or transferrin saturation (TSAT) < 20% were randomized to intravenous ferric derisomaltose (FDI) or usual care. Relationships were investigated between baseline anaemia severity, ferritin and TSAT, to changes in haemoglobin from baseline to 4 months, Minnesota Living with Heart Failure (MLwHF) score and 6-minute walk distance achieved at 4 months, and clinical events, including heart failure hospitalization (recurrent) or cardiovascular death. RESULTS: The rise in haemoglobin after administering FDI, adjusted for usual care, was greater for lower baseline TSAT (Pinteraction < .0001) and ferritin (Pinteraction = .028) and more severe anaemia (Pinteraction = .014). MLwHF scores at 4 months were somewhat lower (better) with FDI for more anaemic patients (overall Pinteraction = .14; physical Pinteraction = .085; emotional Pinteraction = .043) but were not related to baseline TSAT or ferritin. Blood tests did not predict difference in achieved walking distance for those randomized to FDI compared to control. The absence of anaemia or a TSAT ≥ 20% was associated with lower event rates and little evidence of benefit from FDI. More severe anaemia or TSAT < 20%, especially when ferritin was ≥100 µg/L, was associated with higher event rates and greater absolute reductions in events with FDI, albeit not statistically significant. CONCLUSIONS: This hypothesis-generating analysis suggests that anaemia or TSAT < 20% with ferritin > 100 µg/L might identify patients with heart failure who obtain greater benefit from intravenous iron. This interpretation requires confirmation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Cleland JGF, Kalra PA, Pellicori P, et al. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. Eur Heart J. 2024. PMID: 38446126. doi:10.1093/eurheartj/ehae086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。